The induction of ferroptosis to avoid NRF2-driven cisplatin resistance has appeared as a promising therapy due to the specific upregulation and seeming addiction of NRF2 in cancer cells, and the development of NRF2-specific inhibitors or downstream pathways could open new possibilities for the treatment of HNSCC patients. Here, NFE2L2 is linked to cancer.